When we treat the disease, we help. When we treat the person, we heal…

🚨 In this week's episode Michael Morris from MSKCC joins Brian and Tom for an in-depth review of ARPI development across the spectrum of prostate cancer. 🍎 Apple Podcasts: buff.ly/NW9htD1 🎧Spotify: buff.ly/XASyv8K

✍️Mark your calendar for our next upcoming space❗️ Navigating ASH: Tips, Strategy, and What to Expect‼️ Speakers: Agrima Mian and Charlotte Story Host: Shreyas Kalantri, MD ⏰Monday, December 1st, 2025 📍X space at 6 pm EST

2 things stood out to me re: CRC in this AYA study. 1. CRC has HIGHEST lifetime metastatic burden of all cancers (~44%!) 2. AYA CRC w more late recurrences, steadily rising to yr 5. >>implications re surveillance, survivorship, & potential role of metastasis directed therapy.

In our “Challenging Cases” 🗣️ we touch on 2L & beyond for RCC w/ David Braun!“What next” after dual ICI or IO+TKI? ✅ Sequencing ✅ Data post IO ✅ AEs & management Full 🗣️: ⭐️ Oncbrothers.com/cc-rcc-secondl… ⭐️ “Oncology Brothers” podcast #OncTwitter #gusm OncUpdates OncoAlert

What options/data do we have post dual ICI or IO + TKI in RCC? Besides these studies 👇👇 one could also extrapolate Tivozanib’s activity post IO from TiNivo-2 Study (Toni Choueiri, MD et al.) and Cabozantinib activity from CONTACT-03 study (Sumanta K. Pal, MD, FASCO et al.)! #OncTwitter #gusm

Join me and my esteemed colleague Dr. Marina Garassino in this interactive discussion on Squamous NSCLC on December 6 at 11:45 am Central time (Live or Virtually) from Chicago during the North American Conference on Lung Cancer. You can register at answersincme.com/CME-ONC-03650.

Sharing results from one of my first clinical trials supported by ACS National Lung Cancer Roundtable - the #CALM trial (Coordinate a Lung Screening With Mammography) - where we tested a novel approach: pairing routine mammography visits with lung cancer screening (LCS) outreach. Mount Auburn Hospital Internal Medicine Residency Harvard Medical School

Epcoritamab (SubQ) is now U.S. FDA ✅ for 2L in follicular lymphoma based off #EPCOREFL1! We 🗣️ this trial, findings, StepUp dosing, & AEs w/ #GillesSalles Full 🗣️: ⭐️ oncbrothers.com/fda-epcoritama… ⭐️ Also on “Oncology Brothers” podcast OncoAlert OncUpdates #HemeTwitter #ASH25

Join the Oncology Brothers and this great lineup ASH for Advancements in Oncology on Sunday, December 7, 2025, at 7:00 - 9:30 PM ET for great discussions on leukemia, lymphoma, and (of course 😀) #myeloma. Spread the word/RT! #mmsm

ADC development in urothelial cancer has led to a number of new agents (EGFR/HER2 ADCs NECTIN4/TOPO1) being explored. There has been little focus on biomarkers and more on doublets and triplets. This podcast from #UromigosLive summarised the landscape. podcasts.apple.com/gb/podcast/the…

Excited to present and attend at #ASH25! Awesome event highlights from one of my star 🤩cofellows Agrima Mian and the #ASHTraineeCouncil! Also would recommend Oncology Brothers Live Event! Please share any other recommended events you have for trainees! #MedTwiter #OncTwitter

Going to be at #ASH25? Look forward to seeing you at #AdvInOnc25 to 🗣️ the current SoC & how the new data will change/reinforce our practice!! In Person: Dec 7, 2025 ⏰: 7:00-9:30PM Register: bit.ly/aioash25 #HemeTwtitter #mmsm #lymsm OncoAlert Dr. Uma Borate: Associate Professor

For #ASH25 attendees I’ve been on this platform for 16 years. Here are some tips on how to be productive, and gain influence and credibility on X. 1) Highlight new information, but also give your take on it as well. Thats what makes the content interesting. 2) Be active

These are excellent trials to look out for as far as important breast cancer updates. I’ll keep you posted as they get presented on my thoughts!!! #bcsm

First up is calliecoombs and Bita Fakhri with discussions on #CLL with the Oncology Brothers Advancements in Oncology! #MedTwitter #MedX #HemeTwitter #AdvInOnc25 SignifyMD

PACKED house at the Oncology Brothers #AdvInOnc25! One of the best ways for trainees to learn about how the research presented at #ASH25 will impact patient care! #MedTwitter #HemeTwitter @vincentRK Robert Z. Orlowski Jorge Cortes MD Anna Sureda Andrew M. Evens, DO, MBA, MSc calliecoombs Bita Fakhri

🙌🙌 Off to a great start with Dr Coombs and Fakhri on a great #CLL discussion as well as Agrima Mian interviewing Perlmutter Cancer Center at NYU Langone Health Dr Samuel Yamshon on key #ASH25 data. More to come!

Next up, moving on to Lymphoma panel discussion with Andrew M. Evens, DO, MBA, MSc and Dr.Durani! HUGE shoutout to Dr. Urshila Durani from Mayo Clinic for stepping in last minute! #MedTwitter #HemeTwitter #MedX #AdvInOnc25 #CommunityOncology #lymsm

Next up Dr. Uma Borate: Associate Professor and Jorge Cortes MD dive into discussion on #Leukemia with the Oncology Brothers! Discussion includes trials presented at #ASH25 such as PARADIGM, EVOLVE-1, and ALIDHE for #AML and ASC4First in #CML #MedTwitter #HemeTwitter #CommunityOncology #AdvInOnc25 #MedX